Baxter 2021 Corporate Responsibility Report 52 Appendix 2030 Corporate Responsibility Goals Corporate Responsibility Commitment Empower Our Patients Protect Our Planet Champion Our People and Communities Introduction Cross-Cutting Commitments Appendix: About This Report EXTERNAL REPORTING STANDARDS To develop our corporate responsibility reporting approach, we have considered the disclosure frameworks and guidance of leading sustainability standards and reporting organizations, including the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), the United Nations Sustainable Development Goals and third- party raters and rankers focused on environmental, social and governance issues. We were one of the first companies to pilot the GRI Sustainability Reporting Guidelines, in 1999, and belong to the GRI Community. We referenced the GRI Sustainability Reporting Standards in the development of this report. See the GRI Content Index for detail. In addition, this report includes our SASB disclosure , based on the SASB Medical Equipment and Supplies Sustainability Accounting Standard. FEEDBACK Readers of this report can provide comments and suggestions to us via email: corporate responsibility [email protected] . SCOPE OF THIS REPORT The performance and other data in this report are from calendar year 2021 unless stated otherwise. Some examples and program descriptions include information from 2022. • This report covers Baxter’s global operations, including subsidiaries, unless stated otherwise. Environmental, health, safety and sustainability data include joint ventures where we have a controlling interest. • The content in this report refers to Baxter and does not include Hillrom, unless stated otherwise. Our 2022 Corporate Responsibility Report will reflect the combined company. • All currency in this report is in U.S. dollars unless stated otherwise. • Significant restatements of data compared with prior years are noted in the sections where they appear. • All references to “new product launches” in this report include new product launches, line extensions and geographical expansions, unless otherwise noted. • This report is intended for global use. Please consult the appropriate country-specific Baxter website for information regarding activities in that country. • Some statements in this report about products or procedures may differ from the licensed indi- cations in specific countries. Therefore, always consult the country-specific summary of product characteristics, package leaflets or instructions for use. For more information, please contact a local Baxter representative. FORWARD-LOOKING STATEMENTS This report contains forward-looking statements concerning Baxter, including with respect to compliance, future performance, our 2030 Corporate Responsibility Commitment and other plans and initiatives. These statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the impact of global economic conditions (including potential trade wars and economic sanctions) and public health crises and epidemics, such as the ongoing coronavirus (COVID-19) pandemic, on us and our employees, customers and suppliers, including foreign governments in countries in which we operate; demand for and market acceptance of risks for new and existing products; product development risks (including any delays in obtaining required regulatory approvals or failures to obtain such approvals); product quality or patient safety concerns; continuity, availability and pricing of acceptable raw materials and component supply; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, geopolitical crises, regulatory actions or otherwise; accurate identification of and execution on business development and R&D opportunities and realization of anticipated benefits (including the acquisitions of Cheetah Medical, Seprafilm Adhesion Barrier, specified OUS rights to Caelyx / Doxil formulations, full U.S. and specific OUS rights to Transderm Scop scopolamine patch, PerClot hemostat, Hillrom and certain rights to Zosyn in the U.S. and Canada); breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the adequacy of our cash flows from operations (which may be negatively impacted by collectability concerns as a result of the ongoing COVID-19 pandemic or otherwise) and other sources of liquidity to meet our ongoing cash obligations and fund our investment program; loss of key employees or inability to identify and recruit new employees; future actions of regulatory bodies and other governmental authorities, including FDA, the Department of Justice, the SEC, the New York Attorney General and foreign regulatory agencies, including the continued delay in lifting the warning letter at our Ahmedabad facility; the outcome of pending or future litigation, including the opioid litigation and current and future ethylene oxide litigation or other claims; proposed regulatory changes of the U.S. Department of Health and Human Services in kidney health policy and reimbursement, which may substantially change the U.S. end-stage renal disease market and demand for our peritoneal dialysis products, necessitating significant multiyear capital expenditures, which are difficult to estimate in advance; failures with respect to compliance programs; future actions of third parties, including payers; U.S. healthcare reform and other global austerity measures; pricing, reimbursement, taxation and rebate policies of government agencies and private payers; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; fluctuations in foreign exchange and interest rates; the ability to enforce owned or in- licensed patents or the prevention or restriction of the manufacture, sale or use of products or technology affected by patents of third parties; global trade and tax policies; any change in laws concerning the taxation of income (including current or future tax reform), including income earned outside the United States and potential taxes associated with the Base Erosion and Anti-Abuse Tax or the Build Back Better framework; actions taken by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.